Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
Xeris to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab CHICAGO–(BUSINESS WIRE)–#GvokeHypoPen–Xeris Biopharma Holdings, Inc….
Vitalist Inc. Partners with Pattern to Accelerate Global E-Commerce Growth for Reebok Smartwatches